# Celldex Therapeutics Inc. (CLDX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.95B  
**Price:** $29.35 (-0.84%)

> Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases. Its research platforms leverage novel antibody therapeutics, antibody-drug conjugates, and immune-activating agents designed to engage the patient's immune system and deliver precise cytotoxic activity. Key product candidates include barzolvolimab, an investigational monoclonal antibody targeting KIT for chronic spontaneous urticaria and other mast cell-mediated disorders; glembatumumab vedotin, an antibody-drug conjugate against glycoprotein NMB for certain breast and skin cancers; varlilumab, an agonist antibody targeting CD27 to enhance immune responses; CDX-301, a recombinant human Flt3 ligand to expand dendritic and immune cell populations; CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells; and CDX-0159, part of the anti-KIT program. Celldex Therapeutics Inc. advances these programs through clinical trials in oncology, neurology, and inflammatory diseases, primarily serving patients in North America via collaborations with academic centers and industry partners. Founded in 1983 and headquartered in Hampton, New Jersey, it plays a vital role in the biotechnology sector by pioneering next-generation immunotherapies.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2M | $1M | -$287M | -$259M | — |
| 2024 | $7M | $7M | -$195M | -$158M | — |
| 2023 | $7M | $7M | -$155M | -$141M | — |
| 2022 | $2M | $2M | -$115M | — | — |
| 2021 | $5M | $5M | -$71M | — | — |
| 2020 | $7M | $7M | -$63M | — | — |
| 2019 | $4M | $3M | -$55M | — | — |
| 2018 | $10M | $9M | -$156M | — | — |
| 2017 | $13M | $12M | -$122M | — | — |
| 2016 | $7M | $5M | -$133M | — | — |
| 2015 | $5M | — | -$130M | — | — |
| 2014 | $4M | — | -$122M | — | — |
| 2013 | $4M | — | -$81M | — | — |
| 2012 | $11M | — | -$58M | — | — |
| 2011 | $9M | — | -$43M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $583M | $56M | $527M | $29M | — |
| 2024 | $792M | $45M | $747M | $28M | — |
| 2023 | $466M | $36M | $429M | $35M | — |
| 2022 | $353M | $27M | $326M | $29M | — |
| 2021 | $445M | $25M | $419M | $39M | — |
| 2020 | $236M | $26M | $209M | $44M | — |
| 2019 | $123M | $29M | $94M | $11M | — |
| 2018 | $156M | $32M | $124M | $24M | — |
| 2017 | $316M | $79M | $236M | $40M | — |
| 2016 | $383M | $118M | $265M | $42M | — |
| 2015 | $338M | $47M | $290M | $72M | — |
| 2014 | $248M | $36M | $212M | $28M | — |
| 2013 | $347M | $27M | $320M | $169M | — |
| 2012 | $126M | $30M | $96M | $25M | — |
| 2011 | $98M | $29M | $69M | $12M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$211M | $3M | -$214M |
| 2024 | -$158M | $2M | -$160M |
| 2023 | -$107M | $2M | -$109M |
| 2022 | -$104M | $2M | -$106M |
| 2021 | -$61M | $1M | -$62M |
| 2020 | -$40M | $2M | -$42M |
| 2019 | -$46M | $731,000 | -$47M |
| 2018 | -$75M | $813,000 | -$76M |
| 2017 | -$100M | $2M | -$102M |
| 2016 | -$113M | $3M | -$116M |
| 2015 | -$99M | $5M | -$104M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CLDX)